Comprehensive analysis of disease pathology in immunocompetent and immunocompromised hosts following pulmonary sars-cov-2 infection

HIGHLIGHTS

• who: Santhamani Ramasamy et al. from the Manassas, MA, USA) [14, ]Experiments involving infectious SARS-Co, were conducted in Biosafety level , facilities at Rutgers University, as per approved standard operating procedures. Unless specified, all chemicals and reagents were purchased from Sigma-Aldrich (Sigma-Aldrich, St. Louis, MO, USA)., .2. SARS-Co, Infectivity Titration We performed a plaque assay to determine live viruses in the inoculum and tissue homogenates, as described previously [16]. The Vero , cell monolayer was infected with SARS-Co, using DMEM media (supplemented with, % FBS). The plaques were visualized on the, rd day by staining . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.